Croissy-Beaubourg and Montpellier, February 3, 2015 – Theradiag (ISIN:
FR0004197747, Ticker: ALTER), a company specializing in theranostics and in
vitro diagnostics, announces today that it has entered into a master
services agreement with the biopharmaceutical company UCB, with a first
application for the anti-TNF biologic certolizumab pegol (the brand name
Cimzia®).
Under the terms of the master services agreement, Theradiag will perform
services for UCB on a project basis. A first project has already been conducted
to determine the comparability of Theradiag’s LISA TRACKER tests with tests
performed by UCB in clinical trials for the monitoring of drug levels and
anti-drug antibodies in human plasma. The results of this performance study
confirmed the suitability of Theradiag’s theranostic kit for monitoring patients
treated with certolizumab pegol. The study was sponsored by UCB.
“We are extremely pleased to have entered into this services agreement
with UCB, one of the leading biopharmaceutical companies engaged in the
treatment of auto-immune diseases. The success of the performance study shows
that LISA TRACKER tests could potentially be included in pharmaceutical clinical
trials in the future. This is excellent news for our research teams who have
developed the theranostics kits, as well as for our investors, since this
agreement constitutes a driver of growth for Theradiag’s theranostics sales in
Europe and the rest of the world” commented Michel Finance, Chief Executive
Officer of Theradiag.
To read more information please click on this link to view the full THERADIAG and UCB enter into a master services agreement